GBT Announces Participation at the Cantor Global Healthcare Conference
September 20 2021 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will participate in a virtual fireside chat at
the Cantor Global Healthcare Conference on Monday, September 27,
2021, at 2:40 p.m. ET.
The fireside chat will be webcast live from GBT’s website at
www.gbt.com in the Investors section. A replay of the webcast will
be archived and available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company
dedicated to the discovery, development and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor) tablets, the first FDA-approved
treatment that directly inhibits sickle hemoglobin polymerization,
the root cause of red blood cell sickling in SCD. GBT is also
advancing its pipeline program in SCD with inclacumab, a P-selectin
inhibitor in Phase 3 development to address pain crises associated
with the disease, and GBT021601 (GBT601), the company’s
next-generation hemoglobin S polymerization inhibitor. In addition,
GBT’s drug discovery teams are working on new targets to develop
the next wave of potential treatments for SCD. To learn more,
please visit www.gbt.com and follow the company on Twitter
@GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney
Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024